APOE · rs429358
Where this position leads
Conditions: Alzheimer's Disease Risk (APOE), Osteoarthritis
Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.
What ClinVar records
Classification
Conflicting classifications of pathogenicity; other; risk factor for Alzheimer disease 2, Primary degenerative dementia of the Alzheimer type, presenile onset, Warfarin response, Alzheimer disease, Alzheimer disease 4 and 2 more; criteria provided, conflicting classifications (1 of 4 stars, 18 submitters), last evaluated 2026-01-26.
ClinVar record 17864 NM_000041.4(APOE):c.388T>C (p.Cys130Arg)
Classification
no classification for the single variant; no classification for the single variant (0 of 4 stars).
ClinVar record 694742 NM_000041.4(APOE):c.388= (p.Cys130=)
What this is ClinVar's aggregate record for this position (as of its 2026-10-19 release), not a result about you. A classification describes the variant against the condition named, as laboratories submitted it. Whether a person carries this variant, and what that would mean for them, is a question for a clinical test and a genetic counsellor.
What people read about alongside this
Papers in Europe PMC whose title or abstract names both this rsID and that subject. A shared paper means somebody wrote about the two together — it is not a claim that this position explains the subject.
2026-08-31 · medicalxpress.com, reporting on Washington University in St. Louis (Belloy et al.)
Scientists identify genes that could reduce APOE4 Alzheimer's disease risk
Directly about APOE4 carriers, this page's own genotype (rs429358/rs7412). Not a treatment yet -- early-stage genomic analysis identifying drug targets, not a drug approval or trial result -- flagged as such on the page.
2026-07-14 · Eisai / Biogen (FDA supplemental approval)
Direct follow-on to this session's own apoe4-testing-before-alzheimers-drugs blog post -- APOE4 genotype-stratified ARIA risk is why pre-treatment genotyping matters, and this news is a real regulatory change to how lecanemab treatment starts. No usable thumbnail found after multiple source fetch attempts (403/paywall/empty on Eisai, Biogen, NeurologyLive, AJMC, Medscape, alzimpact.org) -- this is the first real test of the site-favicon fallback added the same day.
2026-06-03 · EADB, et al., Nature Genetics 2026, PMID:42237039
Nine research consortia pooled their European-ancestry studies: 128,681 cases or proxy cases of Alzheimer's disease and related dementias and 849,833 controls. The analysis identified 91 loci, 16 of them new; 56 were detected specifically in clinically diagnosed Alzheimer's disease, and a further 18 are listed as needing outside validation. A polygenic score built from the loci other than APOE went with Alzheimer's pathology rather than other kinds: people in the top tenth of the score had about twice the risk of advanced tangle and plaque pathology at death, compared with people in the middle of the range. 69 of the study's positions are already on this site, 59 of them on the Alzheimer's disease page, including rs429358 (APOE), rs7232 (MS4A6A) and rs17462136 (CASS4). PMID:42237039.
2026-04-30 · Londono-Correa D, et al., Nature Communications 2026, PMID:42062297
Cognitive ability is usually studied as one thing. This study split performance on cognitive tests into three parts — reaction time, fluid reasoning (working out something new) and crystallized knowledge (what a person has learned) — and reports a genome-wide analysis of crystallized knowledge in about 439,000 people. Schizophrenia, bipolar disorder, autism, ADHD and Alzheimer's disease were each genetically correlated with the three parts, and with a non-cognitive factor tied to educational attainment, but the size and even the direction of the correlation depended on which part and which disorder. 10 of the study's positions are already on this site, including rs34316 (MEF2C), filed here under educational attainment, and rs429358 (APOE), which the study reports for fluid reasoning. PMID:42062297.
rs429358 is a single position in the genome, in or near the APOE gene. Published research associates it with lewy body disease. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
On MyGeneLog this position is linked to Alzheimer's Disease Risk (APOE), Osteoarthritis. The research behind each link, and its sources, are set out on that condition page.
APOE carries pharmacogenomic findings for Lecanemab and other anti-amyloid antibodies. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
Subjects that appear in the title or abstract of the same papers as this rsID include heart and circulation (32 papers), brain and memory (29 papers), cholesterol and blood fats (27 papers), blood sugar and insulin (23 papers), learning and focus (16 papers). A shared paper means somebody wrote about the two together; it is not a claim that this position explains the topic.
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
GWAS Catalog, PLoS Genet 2014, PMID:25188341. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Lewy body disease (rs429358). MyGeneLog™. https://www.mygenelog.com/variants/rs429358